Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions

American Journal of Veterinary Research

Volumn 68, Issue 7, 2007, Pages 709-715

  Chan, Pooi See ^a,b   Caron, John P ^a   Orth, Michael W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; AGGRECANASE 1; AGGRECANASE 2; CHONDROITIN SULFATE; COLLAGEN TYPE 2; COLLAGENASE 3; CYCLOOXYGENASE 2; FCHG 49; GLUCOSAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; RECOMBINANT INTERLEUKIN 1BETA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRH 122; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CARTILAGE; CONTROLLED STUDY; COW; CULTURE MEDIUM; DOWN REGULATION; EXPLANT; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; REAL TIME POLYMERASE CHAIN REACTION; TISSUE CULTURE; UPREGULATION;

ADAM PROTEINS; ANIMALS; CARTILAGE, ARTICULAR; CATTLE; CHONDROITIN SULFATES; COLLAGEN TYPE II; CULTURE MEDIA; CYCLOOXYGENASE 2; DINOPROSTONE; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; GLUCOSAMINE; INTERLEUKIN-1BETA; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MATRIX METALLOPROTEINASES; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PROCOLLAGEN N-ENDOPEPTIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE CULTURE TECHNIQUES; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

BOVINAE;

EID: 34547453184     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.7.709     Document Type: Article

References (42)

1. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001;44:585-594.
2. Tortorella MD, Malfait AM, Deccico C, et al. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001;9:539-552.
3. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993;94:145-149.
4. Campbell IK, Piccoli DS, Hamilton JA. Stimulation of human chondrocyte prostaglandin E2 production by recombinant human interLeukin-1 and tumour necrosis factor. Biochim Biophys Acta 1990;1051:310-318.
5. Stadler J, Stefanovic-Racic M, Billiar TR, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991;147:3915-3920.
6. Morisset S, Patry C, Lora M, et al. Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol 1998;25:1146-1153.
7. Kojima F, Naraba H, Miyamoto S, et al. Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with OA. Arthritis Res Ther 2004;6:R355-R365.
8. Mendes AF, Carvalho AP, Caramona MM, et al. Role of nitric oxide in the activation of NF-kappaB, AP-1 and NOS II expression in articular chondrocytes. Inflamm Res 2002;51:369-375.
9. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
10. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-38S.
11. Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164:85-91.
12. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of OA: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469-1475.
13. Hungerford DS, Jones LC. Glucosamine and chondroitin sulfate are effective in the management of OA. J Arthroplasty 2003;18:5-9.
14. Canapp SO Jr, McLaughlin RM Jr, Hoskinson JJ, et al. Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate. Am J Vet Res 1999;60:1552-1557.
15. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee OA. N Engl J Med 2006;354:795-808.
16. Lippiello L, Woodward J, Karpman R, et al. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000;381:229-240.
17. Orth MW, Peters TL, Hawkins JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine Vet J Suppl 2002;34:224-229.
18. Chan PS, Caron JP, Orth MW. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am J Vet Res 2005;66:1870-1876.
19. Chan PS, Caron JP, Rosa GJ, et al. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage 2005;13:387-394.
20. Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) 2005;230:255-262.
21. Adebowale A, Du J, Liang Z, et al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002;23:217-225.
22. Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm Drug Dispos 2004;25:109-116.
23. Laverty S, Sandy JD, Celeste C, et al. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 2005;52:181-191.
24. Biggee BA, Blinn CM, McAlindon TE, et al. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006;65:222-226.
25. Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005;13:1041-1049.
26. Fenton JI, Chlebek-Brown KA, Peters TL, et al. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000;8:258-265.
27. Blanco FJ, Ochs RL, Schwarz H, et al. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 1995;146:75-85.
28. Reno C, Marchuk L, Sciore P, et al. Rapid isolation of total RNA from small samples of hypocellular, dense connective tissues. BioTechniques 1997;22:1082-1086.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
30. SAS user's guide: statistics, version 8.2 edition. Cary, NC: SAS Institute Inc, 2006.
31. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-284.
32. Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 2006;33:1329-1340.
33. Hua J, Suguro S, Hirano S, et al. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 2005;54:127-132.
34. Amin AR, Attur M, Abramson SB. Nitric oxide synthase and cyclooxygenases: distribution, regulation, and intervention in arthritis. Curr Opin Rheumatol 1999;11:202-209.
35. Homandberg GA, Guo D, Ray LM, et al. Mixtures of glucosamine and chondroitin sulfate reverse fibronectin fragment mediated damage to cartilage more effectively than either agent alone. Osteoarthritis Cartilage 2006;14:793-806.
36. Gendron C, Kashiwagi M, Hughes C, et al. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett 2003;555:431-436.
37. Homandberg GA, Wen C. Exposure of cartilage to a fibronectin fragment amplifies catabolic processes while also enhancing anabolic processes to limit damage. J Orthop Res 1998;16:237-246.
38. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under simulated conditions of joint stress. Osteoarthritis Cartilage 2003;11:335-342.
39. Nakamura H, Shibakawa A, Tanaka M, et al. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in OA. Clin Exp Rheumatol 2004;22:293-299.
40. Fenton JI, Orth MW, Chlebek-Brown KA, et al. Effect of longeing and glucosamine supplementation on serum markers of bone and joint metabolism in yearling quarter horses. Can J Vet Res 1999;63:288-291.
41. Caron JP, Peters TL, Hauptman JG, et al. Serum concentrations of keratan sulfate, osteocalcin, and pyridinoline crosslinks after oral administration of glucosamine to standardbred horses during race training. Am J Vet Res 2002;63:1106-1110.
42. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee OA: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-1155.